Medical Student Research Fellowship for Summer 2008
Mentor: Sergio Huerta, M.D., F.A.C.S.
Department: Surgery
Room number: E07.126
Mail Code: 9156
Phone number: 214 857-1800
E-mail: Sergio.Huerta@UTsouthwestern.ed
Project title: Factors that lead to radiation resistance in rectal cancer
Human subjects IRB approved project number (where applicable): 052007-035
Animal subjects IRB approved project number (where applicable):
Project Type (patient-based research, animal-based research, or basic research; this characterization is only to permit a general classification for grouping similar types of projects)
Project Type: Basic Science
Brief Description of Project:
In spite of current aggressive multimodality treatments in rectal cancer, recurrence
and mortality rates are unacceptably high. Efforts to improve local control
and survival in rectal cancer are the focus of multiple current clinical and
research efforts. Radiotherapy is currently used as a (neo-) adjuvant modality
for rectal carcinoma to aid with surgical intervention or to prevent recurrence,
respectively. Pre- intra- or post- operative radiation therapy, however, either
alone or in combination with chemotherapy results in a tremendously wide clinical
response with nearly 10% of patients achieving complete pathological response
and up to nine percent non-responders. Experimental data from my laboratory
suggests that in colorectal cancer cells, an increased ratio of anti-apoptotic
IAPs (survivin, XIAP) to pro-apoptotic Smac-DIABLO results a radioresistant
phenotype. The overall goal of our research protocol is to understand the factors
that lead to radiation resistance with the hypothesis the IAP/Smac-DIABLO ratio
is affected as indicated by our preliminary studies in vitro. The present protocol
will investigate the effects of radiation response based on the expression of
XIAP, survivin and Smac-DIABLO ex vivo in rectal cancer tissues patients who
underwent surgery for the treatment of rectal cancer. Tissue will be collected
from tumors already identified at the Parkland Memorial Hospital (PMH) from
archived tissues from patients who underwent surgery for the management of rectal
cancer. Tumors will be examined after surgical resection from tissue obtained
directly from paraffin-embedded tissue from the tumor to determine the protein
levels of survivin, XIAP and Smac-DIABLO by tissue microarray. The medical records
of each patient will be interrogated to determine clinical response to radiation
treatment as well as the rate of morbidity and mortality. These parameters will
be correlated to the levels of expression of survivin, XIAP and Smac-DIABLO.